GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reata Pharmaceuticals Inc (NAS:RETA) » Definitions » Quick Ratio

Reata Pharmaceuticals (Reata Pharmaceuticals) Quick Ratio : 3.19 (As of Jun. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Reata Pharmaceuticals Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Reata Pharmaceuticals's quick ratio for the quarter that ended in Jun. 2023 was 3.19.

Reata Pharmaceuticals has a quick ratio of 3.19. It generally indicates good short-term financial strength.

The historical rank and industry rank for Reata Pharmaceuticals's Quick Ratio or its related term are showing as below:

RETA' s Quick Ratio Range Over the Past 10 Years
Min: 1.07   Med: 3.4   Max: 13.57
Current: 3.19

During the past 10 years, Reata Pharmaceuticals's highest Quick Ratio was 13.57. The lowest was 1.07. And the median was 3.40.

RETA's Quick Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.485 vs RETA: 3.19

Reata Pharmaceuticals Quick Ratio Historical Data

The historical data trend for Reata Pharmaceuticals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reata Pharmaceuticals Quick Ratio Chart

Reata Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.12 3.49 7.11 11.05 6.75

Reata Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.60 8.78 6.75 6.09 3.19

Competitive Comparison of Reata Pharmaceuticals's Quick Ratio

For the Biotechnology subindustry, Reata Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reata Pharmaceuticals's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reata Pharmaceuticals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Reata Pharmaceuticals's Quick Ratio falls into.



Reata Pharmaceuticals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Reata Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Quick Ratio (A: Dec. 2022 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(397.77-0)/58.96
=6.75

Reata Pharmaceuticals's Quick Ratio for the quarter that ended in Jun. 2023 is calculated as

Quick Ratio (Q: Jun. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(401.849-2.942)/125.093
=3.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reata Pharmaceuticals  (NAS:RETA) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Reata Pharmaceuticals Quick Ratio Related Terms

Thank you for viewing the detailed overview of Reata Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Reata Pharmaceuticals (Reata Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
5320 Legacy Drive, Plano, TX, USA, 75024
Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.
Executives
Steven Ryder director 234 CHURCH STREET, SUITE 1020, NEW HAVEN CT 06510
Antal Rohit Desai director, 10 percent owner C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CITY CA 94065
Rajiv Patni officer: EVP, Chief R&D Officer C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Bhaskar Anand officer: SVP, Chief Accounting Officer 5320 LEGACY DRIVE, PLANO TX 75024
Manmeet Singh Soni officer: COO, CFO and President C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Martin Edwards director 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Dawn Carter Bir officer: Chief Commercial Officer C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DRIVE, SUITE 150, IRVING TX 75063
Christy J. Oliger director 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Andrea Loewen officer: SVP, Global Regulatory Affairs C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Shamim Ruff director 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Mcclellan William D. Jr. director C/O APOLLO ENDOSURGERY, INC., 1120 S., CAPITAL OF TEXAS HWY, BLDG. 1, SUITE 300, AUSTIN TX 78746
Michael D Wortley officer: See Remarks 5320 LEGACY DRIVE, PLANO TX 75024
Meyer Colin John officer: See Remarks C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DR. SUITE 150, IRVING TX 75063
Biogen Inc. other: See footnotes 225 BINNEY STREET, CAMBRIDGE MA 02142
Samina Khan officer: SVP, Chief Medical Officer 5320 LEGACY DRIVE, PLANO TX 75024

Reata Pharmaceuticals (Reata Pharmaceuticals) Headlines

From GuruFocus